News & Updates
![FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder](https://solvdhealth.com/wp-content/uploads/SolvdWebsiteFDAThumbnail.jpg)
FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder
December 19, 2023 — Today, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD).
![SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-White.jpg)
SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists
June 1, 2021 — Dr. Keri Donaldson was recognized by his peers for his outstanding contributions to clinical science in research, teaching, and service.
![SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test](https://solvdhealth.com/wp-content/uploads/News_Blue_SOLVD_Health.jpg)
![SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test](https://solvdhealth.com/wp-content/uploads/News_Blue_SOLVD_Health.jpg)
SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test
January 6, 2021 — The PREVENT clinical trial will enroll up to 12,000 individuals to validate the test, LifeKit Prevent, for the detection of colorectal cancer and adenomas. Subjects will include adults at average-risk for colorectal cancer between the ages of 45 and 84.
![SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-White.jpg)
![SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-White.jpg)
![SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-White.jpg)
Prescient Medicine Holdings is Now SOLVD Health
December 1, 2020 — The new name and brand reflect the company’s mission to solve some of healthcare’s biggest challenges through preventative health solutions that combine genetics-based patient insights with cutting-edge technologies.
![Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic](https://solvdhealth.com/wp-content/uploads/Pharmacy-Times.jpg)
![Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic](https://solvdhealth.com/wp-content/uploads/Pharmacy-Times.jpg)
Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic
September 21, 2020 — Pharmacy Times® interviewed Keri Donaldson, medical director and CEO of Prescient Medicine, about the effects of the current coronavirus disease 2019 (COVID-19) pandemic on the ongoing opioid epidemic in the United States.
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening
June 2, 2020 — The aim of the collaboration is to study microbial biomarkers to identify the presence of precancerous adenomas and carcinomas in the colon.
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
Prescient Medicine and Erasmus MC Partner to Study Opioid Addiction Risk
December 10, 2019 — The partnership will center on Prescient Medicine’s novel genetic testing technology designed to objectively assess an individual’s risk of opioid addiction prior to opioid exposure.
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
FDA Grants Breakthrough Device Designation to Metabiomics Test for the Early Detection of Colon Polyps and Colon Cancer
September 4, 2019 — This Breakthrough Device designation is the first designation for a non-invasive diagnostic test that is designed to detect pre-cancerous polyps, as well as early-stage carcinomas.
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
![Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening](https://solvdhealth.com/wp-content/uploads/Corporate-Logo-Full-Color.jpg)
Prescient Medicine Holdings Inc. Acquires AutoGenomics Inc.
April 23, 2019 — The acquisition of AutoGenomics will enable Prescient Medicine to advance the development and commercialization of a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD).